anc8ed's picture
From anc8ed rss RSS  subscribe Subscribe

Opportunities in human embryonic stem cell (h esc) products 

Opportunities in human embryonic stem cell (h esc) products

 

 
 
Tags:  swine flu  h r block  helicobacter pylori bacteria  triple therapy  gram negative bacterium  cell types  health &amp fitness  h and r block  james harrison  human embryonic stem cell  health articles 
Views:  34
Published:  January 04, 2012
 
0
download

Share plick with friends Share
save to favorite
Report Abuse Report Abuse
 
Related Plicks
Stem Cell Research

Stem Cell Research

From: Lizthomas
Views: 1579 Comments: 0

 
Swine Flu Final

Swine Flu Final

From: conejo25
Views: 400 Comments: 0

 
why sporting floor coverings shield1347

why sporting floor coverings shield1347

From: shoesira5
Views: 11 Comments: 0

 
ANS Special Topic-Stem Cells

ANS Special Topic-Stem Cells

From: CSCanada
Views: 25 Comments: 0

 
John McCain on Stem Cell Research

John McCain on Stem Cell Research

From: anon-61514
Views: 1064 Comments: 0
John McCain on Stem Cell Research
 
Swine Flu H1N1, Advisory-India

Swine Flu H1N1, Advisory-India

From: howyned
Views: 196 Comments: 0

 
See all 
 
More from this user
Finding local lessons in software engineering

Finding local lessons in software engineering

From: anc8ed
Views: 494
Comments: 0

Apps & Iphone/iTouch website and/or article resources

Apps & Iphone/iTouch website and/or article resources

From: anc8ed
Views: 146
Comments: 0

Buy order purchase dimenhydrinate online cheap discount without prescription

Buy order purchase dimenhydrinate online cheap discount without prescription

From: anc8ed
Views: 0
Comments: 0

New Rules for First-Time Homebuyer Tax Credit

New Rules for First-Time Homebuyer Tax Credit

From: anc8ed
Views: 126
Comments: 0

Apple i pad 64gb video tutorial

Apple i pad 64gb video tutorial

From: anc8ed
Views: 247
Comments: 0

Infosys 4QFY2010 Result Update

Infosys 4QFY2010 Result Update

From: anc8ed
Views: 298
Comments: 0

See all 
 
 
 URL:          AddThis Social Bookmark Button
Embed Thin Player: (fits in most blogs)
Embed Full Player :
 
 

Name

Email (will NOT be shown to other users)

 

 
 
Comments: (watch)
 
 
Notes:
 
Slide 1: Opportunities in Human Embryonic Stem Cell (hESC) Products Overview: Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body, providing tremendous therapeutic potential. Human ESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of primate embryonic stem cells occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow human embryonic stem cells derived from human blastocysts. As a result of these significant accomplishments at the University of Wisconsin, the Wisconsin Alumni Research Foundation (WARF) filed a series of landmark patents that have affected the intellectual property landscape ever since. These “composition of matter” patents concerning primate embryonic stem cells are controversial because they are so broad that they cover all human embryonic stem cell lines in the United States, not just the specific stem cell lines developed by James Thompson. Since this time, WARF has been the major “gatekeeper” determining which research product companies have been allowed to conduct research and create commercial products using hESCs. WARF has also been in control of what pharmaceutical companies have been able to develop hESC therapies. Since obtaining its landmark patents in 1998, WARF has only entered into licensing agreements with 27 commercial partners for its intellectual portfolio related to isolating and differentiating hESCs, of which only 15 have been disclosed. 300 academic laboratories have also received agreements for using the technology without charge. The low number of licensing agreements suggests that many companies find WARF’s licensing fees to be unwieldy, which isn’t surprising given that disclosed fees have ranged from $75,000 to more than $250,000, plus annual payments and royalties. While Invitrogen, Becton Dickinson and Chemicon have disclosed licensing agreements with WARF, many research products companies have to explore less costly alternatives – such as circumventing the claims, conducting research off-shore, potential use of abnormal karyotypes, developing embryonic stem cell products for other species, and pursuing strategic collaborations. For more information, please contact : http://www.aarkstore.com/reports/Opportunities-in-Human-Embryonic-Stem-Cell-hESCProducts-32477.html Jessica Aarkstore Enterprise Mobile : +918149852585 Email: Jessica@aarkstore.com

   
Time on Slide Time on Plick
Slides per Visit Slide Views Views by Location